(Erstwhile UTI Pharma & Healthcare Fund) The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors. UTI Healthcare Fund is a Equity - Sectoral fund launched on 28 Jun 99. It is a fund with High risk and has given a Below is the key information for UTI Healthcare Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis UTI Healthcare Fund - G
Scheme Objective
CAGR return of 14.9% since its launch. Ranked 40 in Sectoral category. Return for 2024 was 42.9% , 2023 was 38.2% and 2022 was -12.3% . NAV as on 31 Oct 25 ₹290.848 ↓ -1.53 (-0.52 %) Net Assets (AUM) as on 31 Aug 2025 ₹1,119 Cr. Launch Date 28 Jun 1999 Category Equity - Sectoral Rating ☆ Type Open Ended Fund Risk High AMC UTI Asset Management Company Ltd Alpha Ratio 0.79 Expense Ratio 2.26 % Sharpe Ratio -0.149 Information Ratio 0.1 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹500 Exit Load 0-1 Years (1%),1 Years and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 31 Oct 25 Duration Returns 1 Month 2.3% 3 Month -2% 6 Month 7.7% 1 Year 2% 3 Year 23.8% 5 Year 18% 10 Year 15 Year Since launch 14.9% Historical Annual Returns
Year Returns 2024 42.9% 2023 38.2% 2022 -12.3% 2021 19.1% 2020 67.4% 2019 1.2% 2018 -7.5% 2017 6.2% 2016 -9.7% Growth of 10k Over Years
Date Value 31 Oct 20 ₹10,000 31 Oct 21 ₹12,799 31 Oct 22 ₹12,052 31 Oct 23 ₹14,059 31 Oct 24 ₹22,392 31 Oct 25 ₹22,840 Asset Allocation
Asset Class Value Cash 1.02% Equity 98.98% Sector Allocation
Sector Value Health Care 97.9% Basic Materials 1.07% Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMADrug Manufacturers - Specialty & Generic 10% ₹105 Cr 661,016 Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | 532331Drug Manufacturers - Specialty & Generic 5% ₹60 Cr 250,000
↑ 7,327 Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | 500087Drug Manufacturers - Specialty & Generic 5% ₹60 Cr 400,000 Lupin Ltd (Healthcare)
Equity, Since 28 Feb 25 | 500257Drug Manufacturers - Specialty & Generic 5% ₹52 Cr 270,000 Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Dec 20 | PGHLDrug Manufacturers - Specialty & Generic 4% ₹44 Cr 69,320
↓ -719 Glenmark Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Mar 24 | 532296Drug Manufacturers - Specialty & Generic 4% ₹41 Cr 210,000
↓ -10,000 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | 500124Drug Manufacturers - Specialty & Generic 4% ₹41 Cr 335,000
↓ -25,000 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLANDDrug Manufacturers - Specialty & Generic 4% ₹40 Cr 199,297 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSPMedical Care Facilities 4% ₹39 Cr 53,000 Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 May 21 | ALKEMDrug Manufacturers - Specialty & Generic 4% ₹39 Cr 72,000
Talk to our investment specialistFund Managers
Name Since Tenure Kamal Gada 2 May 22 3.42 Yr. Custodians
Company Address Axis Bank Ltd null Deutsche Bank AG MUMBAI Deitsche bank,Kodak House Stock Holding Corporation of India Mittal Court, ‘B’ Wing,,Nariman Point Registrar & Transfer Agent
KFin Technologies Ltd Address 138 -Suyesh Solitaire, Nr. Podar International School,Kudasan, Gandhinagar, Gujarat FAX N.A Email N.A Administrator Companies
Company Address UTI Asset Management Co Ltd PMS Division, UTI - Tower, “Gn” Block, Bandra Kurla Complex, Mumbai- 400051 Auditors
Company Address S. R. BATLIBOI & Co Express Tower, 6th Floor,Nariman Point,Mumbai All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year UTI Healthcare Fund
Growth ₹290.848
↓ -1.53 7.65 % 2 % 23.75 % 17.96 % UTI Healthcare Fund
Normal Dividend, Payout ₹224.785
↓ -1.18 7.65 % 2 % 23.75 % 17.96 % UTI Healthcare Fund
Normal Dividend, Reinvestment ₹224.785
↓ -1.18 7.65 % 2 % 23.75 % 17.96 % Data as on 31 Oct 25